LifeVac Becomes the First and Only FDA-Authorized Anti-Choking Device

Canada — August 2026 — LifeVac Canada is pleased to announce a major milestone for LifeVac following authorization by the U.S. Food and Drug Administration.

On March 4, 2026, the FDA granted LifeVac De Novo authorization, establishing a new device classification for a “suction anti-choking device as a second-line treatment” intended for use when standard choking rescue protocols have been unsuccessful.

View the official FDA classification: LifeVac — De Novo DEN250012

This decision makes LifeVac the first suction anti-choking device to receive this FDA classification and represents an important advancement in the recognition of suction-based airway clearance technology.

LifeVac is a non-powered, non-invasive suction device designed to help remove an airway obstruction when standard choking rescue procedures are unsuccessful. It requires no electricity, batteries or compressed gas.

The FDA authorization follows an extensive review of LifeVac’s safety, performance and supporting evidence.

While the FDA decision applies specifically to the United States, it represents an important international milestone for LifeVac and further supports the growing recognition of suction-based anti-choking devices as an additional option in choking emergencies.

LifeVac Canada will continue working to improve choking preparedness and access to LifeVac across Canada.

About LifeVac Canada

LifeVac Canada Inc. is the authorized Canadian distributor of LifeVac.

For more information, visit LifeVac.ca or contact info@lifevac.ca.